Cabaletta Bio Inc (CABA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cabaletta Bio Inc (CABA) has a cash flow conversion efficiency ratio of -0.315x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.34 Million) by net assets ($112.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cabaletta Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Cabaletta Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cabaletta Bio Inc (CABA) total liabilities for a breakdown of total debt and financial obligations.
Cabaletta Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cabaletta Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
0.037x |
|
Vivien Corp
KO:002070
|
-0.043x |
|
Sinpas Gayrimenkul Yatirim Ortakligi AS
IS:SNGYO
|
-0.005x |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
-0.011x |
|
CapMan Oyj B
HE:CAPMAN
|
0.000x |
|
SillaJen Inc
KQ:215600
|
-0.040x |
|
Summit Midstream Corporation
NYSE:SMC
|
0.024x |
|
Haverty Furniture Companies Inc
NYSE:HVT
|
0.104x |
Annual Cash Flow Conversion Efficiency for Cabaletta Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cabaletta Bio Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Cabaletta Bio Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $112.05 Million | $-131.08 Million | -1.170x | -102.00% |
| 2024-12-31 | $152.34 Million | $-88.22 Million | -0.579x | -155.45% |
| 2023-12-31 | $236.20 Million | $-53.55 Million | -0.227x | +48.91% |
| 2022-12-31 | $104.52 Million | $-46.38 Million | -0.444x | -53.46% |
| 2021-12-31 | $117.96 Million | $-34.11 Million | -0.289x | -18.33% |
| 2020-12-31 | $109.54 Million | $-26.77 Million | -0.244x | -110.67% |
| 2019-12-31 | $138.32 Million | $-16.05 Million | -0.116x | -126.60% |
| 2018-12-31 | $-10.69 Million | $-4.66 Million | 0.436x | -97.67% |
| 2017-12-31 | $-249.00K | $-4.66 Million | 18.719x | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immu… Read more